Platelet-rich plasma treatment in patients with refractory thin endometrium and recurrent implantation failure: A comprehensive review
- Author:
Min Kyoung KIM
1
;
Haengseok SONG
;
Sang Woo LYU
;
Woo Sik LEE
Author Information
- Publication Type:Review Article
- From:Clinical and Experimental Reproductive Medicine 2022;49(3):168-174
- CountryRepublic of Korea
- Language:English
- Abstract: Refractory thin endometrium and recurrent implantation failure are among the most challenging infertility-related factors hindering successful pregnancy. Several adjuvant therapies have been investigated to increase endometrial thickness and the pregnancy rate, but the treatment effect is still minimal, and for many patients, these treatment methods can be quite costly and difficult to approach. Platelet-rich plasma (PRP) is an autologous concentration of platelets in plasma and has recently been elucidated as a better treatment option for these patients. PRP is rich in cytokines and growth factors, which are suggested to exert a regenerative effect at the level of the injured tissue. Another advantage of PRP is that it is easily obtained from the patient’s own blood. We aimed to review the recent findings of PRP therapy used for patients with refractory thin endometrium and recurrent implantation failure.
